DoMore Diagnostics

DoMore Diagnostics is revolutionizing personalized cancer treatment through the innovative application of artificial intelligence. Based in Oslo, Norway, DoMore Diagnostics is dedicated to making complex treatment decisions simple and accessible for all cancer patients. The company’s core technology utilizes digital biomarkers derived from routine tumor tissue slides, seamlessly integrating into existing pathology workflows. Their lead product, Histotype Px® Colorectal, is a CE-IVDD marked outcome prediction marker specifically designed for stage II and III colorectal adenocarcinoma, guiding the decision-making process regarding adjuvant chemotherapy following surgical resection. Founded in 2021 and supported by prominent international research and leading Norwegian tech investors, DoMore Diagnostics is poised to become a significant contributor to advancements in precision medicine. The company's commitment to innovation extends across specialties like cancer diagnostics, deep learning, and prognostication, ultimately empowering healthcare professionals with the insights needed to deliver optimal patient care. DoMore Diagnostics is setting a new standard for accessible and personalized cancer treatment, driven by a team committed to improving patient outcomes.

DoMore Diagnostics' transformative approach leverages cutting-edge artificial intelligence to predict patient outcomes with exceptional accuracy. The company's focus on seamless integration into existing workflows minimizes disruption and maximizes efficiency for pathologists. This allows for a rapid adoption of advanced diagnostic tools and ultimately benefits both clinicians and patients. The company's commitment to rigorous scientific validation ensures the reliability and clinical utility of its products. Through ongoing research and development, DoMore Diagnostics strives to expand its portfolio of digital biomarkers and address unmet needs in cancer care.

DoMore Diagnostics' dedication to precision medicine and accessible diagnostics positions it as a leader in the evolving healthcare landscape. With its foundation in groundbreaking international research and the support of visionary investors, the company is committed to continuous innovation and expansion. DoMore Diagnostics' Oslo headquarters serves as a hub for its growing team of dedicated professionals, all united in their mission to advance cancer care. We invite you to contact us to create a customized and exclusive company showcase and product listing on our platform, and explore how DoMore Diagnostics can contribute to your success.